News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 13/06/2026 +04			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

All News

Mentions Relevance

06-11	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
06-11	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
05-30	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	GL
05-18	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
05-13	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
05-13	Genmab A/S : has published its Articles of Association	PU
05-12	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
05-12	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
05-11	Genmab - Major Shareholder Announcement	AQ
05-11	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW
05-09	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis
05-08	Genmab says Orbis Investment Management Limited holds 5.08% of Genmab A/S as of May 8, 2026	RE
05-08	Major Shareholder Announcement	GL
05-08	Goldman Sachs raises Genmab price target to DKK 2,300 (2,200), reiterates Buy - BN	FW
05-07	Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Genmab Q1 Net Profit Falls, Revenue Rises	MT
05-07	Genmab A/S, Q1 2026 Earnings Call, May 07, 2026
05-07	Genmab A/S : Investor Presentation - May 2026	PU
05-07	Genmab reports Q1 operating profit of $180 million	RE